Opinion|Videos|July 16, 2024
Lasting Impacts of RSV
An expert on RSV discusses symptoms that warrant emergent medical care and the overall impact of RSV on older adults or immunocompromised individuals.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How should pharmacists counsel patients/caregivers about RSV symptoms that warrant emergent medical care?
- How would you characterize the overall impact of RSV in terms of outcomes on older adults or immunocompromised individuals?
Advertisement
Related to this article
Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
As psychedelic therapies advance through clinical development, pharmacists should prepare for potential roles in their safe, evidence-based integration into patient care.
How oncology pharmacy leaders fight burnout with stay surveys, smarter schedules, and recognition—building resilient teams through loss and turnover.
At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.
In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.
A former residency program director unpacks why this debate keeps resurfacing, and why some reasons people give for skipping residency may not hold up the way they think they do.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: What Pharmacists Need to Know About Treatment
2
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
3
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
4
Could Cemdisiran Keep Patients With Myasthenia Gravis Out of the Hospital?
5